| Tel HaShomer Medical Research Infrastructure and Services Ltd. Patent applications |
| Patent application number | Title | Published |
|---|
| 20120136209 | METHODS AND DEVICES FOR PROVIDING INFORMATION USEFUL IN THE DIAGNOSIS OF ABNORMALITIES OF THE GASTROINTESTINAL TRACT - Disclosed are methods useful for providing information useful in the diagnosis of gastrointestinal abnormalities as well as ingestible devices useful for providing information useful in the diagnosis of gastrointestinal abnormalities. | 05-31-2012 |
| 20120127430 | System And Method For Objective Chromatic Perimetry Analysis Using Pupillometer - The present invention relates to a system, device and a method for objective visual field testing and in particular, to such a system and method in which provides objective chromatic perimetry test or color vision test using a pupillometer. | 05-24-2012 |
| 20120122122 | METHOD OF DIAGNOSING CANCER - A method of diagnosing cancer is provided. The method comprising determining a level of CEACAM1 on isolated peripheral blood lymphocytes (PBLs) of a subject in need thereof, wherein an upregulation of the level of CEACAM1 above a predetermined threshold is indicative of cancer in said subject. | 05-17-2012 |
| 20120029497 | Method and System for Monitoring Ablation of Tissues - A method of monitoring heat damage to a tissue during a heat ablation procedure is disclosed. The method comprising: providing images of the tissue, extracting at least one parameter being indicative of a biological response to heat, and using the parameter(s) for determining the heat damage to the tissue. | 02-02-2012 |
| 20120015870 | PEPTIDES AND COMPOSITIONS FOR PREVENTION OF CELL ADHESION AND METHODS OF USING SAME - Compositions comprising an isolated peptide, which may for example optionally comprise a sequence selected from the group consisting of FDYDWY (SEQ ID NO: 2), SFSQNKSVHSFDYDWYNVSDQADLKN (SEQ ID NO: 3) or CSFSQNKSVHSFDYDWYNVSDQADLKNC (SEQ ID NO: 1), or any cyclized version thereof, and methods of using same, including for treatment of or prevention of formation of microbial biofilms and against adhesion of a cell to a surface. | 01-19-2012 |
| 20120014927 | METHODS AND KITS FOR DETERMINING PREDISPOSITION TO CANCER - Provided are methods and kits for determining predisposition to cancer by determining the presence or absence in a heterozygote form of the KLOTHO functional variant. Also provided are methods of designing treatment and treating cancer based on the increased predisposition to the cancer, and to determine the prognosis of a subject diagnosed with cancer. | 01-19-2012 |
| 20110311495 | ISOLATED POPULATIONS OF RENAL STEM CELLS AND METHODS OF ISOLATING AND USING SAME - Isolated populations of fetal renal stem cells and progenitor cells are provided. Also provided are methods of generating and using these isolated populations of cells. | 12-22-2011 |
| 20110311494 | METHODS OF REPROGRAMMING RENAL CELLS - A method of reprogramming a differentiated renal cell towards a progenitor phenotype is disclosed. The method comprises up-regulating in the differentiated renal cell an expression of at least one pluripotency associated gene and/or at least one renal stem cell associated gene, thereby reprogramming the differentiated renal cell towards a progenitor phenotype. Cell populations generated thereby and uses thereof are also disclosed. | 12-22-2011 |
| 20110236405 | COAGULATION FACTOR MODULATION FOR CONTROLLING TRANSPLANT ORGAN SIZE - A method of modulating transplant organ size in a subject in need thereof is disclosed. The method comprising: (a) administering to the subject an agent capable of modulating an activity or expression of a coagulation factor or an effector thereof; and (b) transplanting the organ into the subject; thereby modulating the transplant organ size in the subject. | 09-29-2011 |
| 20110098554 | Monitoring of convection enhanced drug delivery - A method for determining a response of a tissue to a destructive treatment is disclosed. The method comprises providing magnetic resonance images of the tissue, and using the magnetic resonance images for determining the response of the tissue to the destructive treatment. Also disclosed is a method for monitoring convection during direct convective interstitial infusion using a pharmaceutical composition which comprises a therapeutic agent and an MRI contrast agent. | 04-28-2011 |
| 20110046071 | GLP-1 Receptor Agonists And Related Active Pharmaceutical Ingredients For Treatment Of Cancer - Disclosed are methods and compositions for increasing concentrations of GLP-1 receptor agonists in the body for the treatment of cancer, alone or together with other active pharmaceutical ingredients such as chemotherapeutic agents or hormone-regulating agents. | 02-24-2011 |
| 20100273172 | MICRORNAS EXPRESSION SIGNATURE FOR DETERMINATION OF TUMORS ORIGIN - The present invention provides a process for classification of specific cancers and tumors origin through the analysis of the expression patterns of specific microRNAs and nucleic acid molecules relating thereto. Classification according to a microRNA expression framework allows optimization of treatment, and determination of specific therapy. | 10-28-2010 |
| 20100221348 | THERAPEUTIC USES OF DUNALIELLA POWDER - A method for treating a disease selected from diabetes mellitus and atherosclerosis, and a method for reducing triglycerides and/or increasing HDL cholesterol levels in the plasma of a subject. The method comprises administrating to a subject an effective amount of crude | 09-02-2010 |
| 20100173291 | METHODS AND KITS FOR DETECTING FETAL CELLS IN THE MATERNAL BLOOD - Provided is a method of identifying a trophoblast by detecting in cells of a biological sample, with the proviso that the biological sample does not comprise a placental tissue, expression of a trophoblast marker selected from the group consisting of an annexin IV, a cytokeratin-7, a cytokeratin-8 and a cytokeratin-19; and classifying cells exhibiting expression of the trophoblast marker as trophoblasts. Also provided are methods of detecting a pregnancy in a subject, isolating trophoblasts from biological samples and prenatally diagnosing a conceptus using the identified trophoblasts. | 07-08-2010 |
| 20100172842 | ASSESSMENT OF BLOOD-BRAIN BARRIER DISRUPTION - A method of analyzing a blood-brain barrier of a subject is disclosed. A detectable dose of an MRI contrast agent is administered to the subject, and a plurality of magnetic resonance images of the subject's brain are acquired over a predetermined time-period. Two or more of the magnetic resonance images are compared thereamongst so as to determine variations in concentration of the contrast agent in the brain, and blood-brain barrier function is assessed based on the variations. | 07-08-2010 |
| 20100150868 | Methods of Individually Optimizing Treatment for an Inflammation Associated Disease - A method of individually optimizing a treatment for an inflammation associated disease is provided. The method comprising contacting each of identical white blood cell samples of a subject in need thereof with a different pharmaceutical agent of a plurality of pharmaceutical agents for the inflammation associated disease, so as to allow elicitation of an anti-inflammatory activity in the white blood cell samples; assaying the anti-inflammatory activity in the white blood cell samples; and identifying a pharmaceutical agent of the plurality of pharmaceutical agents eliciting a strongest anti-inflammatory activity, the pharmaceutical agent being the individually optimized treatment for the inflammation associated disease, wherein when the inflammation associated disease is multiple sclerosis the white blood cell samples are inflamed white blood cell samples. Methods of treating an inflammation associated disease are also described. | 06-17-2010 |
| 20090298045 | Method For Selectively Expanding, Selecting And Enriching Stem/Progenitor Cell Populations - A method of producing stem/progenitor cells from human or animal origin. A population, from an embryonic, fetal or adult source, preferably from bone marrow, blood, fat, muscle, heart, intestine, kidney, liver, lung, pancreas, skin or neural tissues, that includes stem/progenitor cells, is treated with one or more first cytostatic or cytotoxic agents to which the stem/progenitor cells are less sensitive than the other cells of the population. Preferably, the agent(s) selectively deplete(s) from the population cells that are negative with respect to expressing a transporter gene of the first agent(s) while sparing cells that are positive with respect to expressing that gene. Preferably, the population also is treated with one or more cytokines and/or growth factors. | 12-03-2009 |
